BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes
Expert Opin Pharmacother. 2024 Feb 26:1-4. doi: 10.1080/14656566.2024.2322527. Online ahead of print.NO ABSTRACTPMID:38407201 | DOI:10.1080/14656566.2024.2322527 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - February 26, 2024 Category: Drugs & Pharmacology Authors: Panagiotis I Georgianos Christodoula Kourtidou Maria Divani Vassilios Liakopoulos Source Type: research
Simnotrelvir as a potential treatment for COVID-19
Expert Opin Pharmacother. 2024 Feb 27:1-5. doi: 10.1080/14656566.2024.2323597. Online ahead of print.ABSTRACTINTRODUCTION: Simnotrelvir is a selective 3-chymotrypsin-like oral protease inhibitor with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).AREAS COVERED: On 18 January 2024, results of a double-blind, randomized, placebo-controlled trial of simnotrelvir as a treatment for mild-to moderate COVID-19-were published, indicating the drug, when given in combination with ritonavir, shortened the time to resolution of symptoms.EXPERT OPINION: Treatment options for most outpatients with mild-to-...
Source: Expert Opinion on Pharmacotherapy - February 23, 2024 Category: Drugs & Pharmacology Authors: Matthew W McCarthy Source Type: research
Impact of bladder cancer family history on the prognosis of patients with Non-Muscle Invasive bladder cancer Treated with Bacillus Calmette-Guerin (BCG)
CONCLUSION: A family history of BC could have an important impact on the response to BCG.PMID:38393775 | DOI:10.1080/14656566.2024.2323609 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - February 23, 2024 Category: Drugs & Pharmacology Authors: Mohamad Abou Chakra Igor Duquesne Michael Peyromaure Sarah L Mott Mohamad Moussa Michael A O'Donnell Source Type: research
Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence
CONCLUSION: Based on this review to date there is limited data to support any specific pharmacological treatments, although the data for cannabinoids is encouraging in those with FXS and in future developments in gene therapy may provide the answer to the search for precision medicine. Treatment must be person-centered and consider the combination of medical, genetic, cognitive and emotional challenges.PMID:38393835 | DOI:10.1080/14656566.2024.2323605 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - February 23, 2024 Category: Drugs & Pharmacology Authors: Lance V Watkins Seungyoun Moon Lisa Burrows Samuel Tromans Julian Barwell Rohit Shankar Source Type: research
Simnotrelvir as a potential treatment for COVID-19
Expert Opin Pharmacother. 2024 Feb 23. doi: 10.1080/14656566.2024.2323597. Online ahead of print.ABSTRACTINTRODUCTION: Simnotrelvir is a selective 3-chymotrypsin-like oral protease inhibitor with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).AREAS COVERED: On 18 January 2024, results of a double-blind, randomized, placebo-controlled trial of simnotrelvir as a treatment for mild-to moderate COVID-19-were published, indicating the drug, when given in combination with ritonavir, shortened the time to resolution of symptoms.EXPERT OPINION: Treatment options for most outpatients with mild-to-mode...
Source: Expert Opinion on Pharmacotherapy - February 23, 2024 Category: Drugs & Pharmacology Authors: Matthew W McCarthy Source Type: research
Impact of bladder cancer family history on the prognosis of patients with Non-Muscle Invasive bladder cancer Treated with Bacillus Calmette-Guerin (BCG)
CONCLUSION: A family history of BC could have an important impact on the response to BCG.PMID:38393775 | DOI:10.1080/14656566.2024.2323609 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - February 23, 2024 Category: Drugs & Pharmacology Authors: Mohamad Abou Chakra Igor Duquesne Michael Peyromaure Sarah L Mott Mohamad Moussa Michael A O'Donnell Source Type: research
Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence
CONCLUSION: Based on this review to date there is limited data to support any specific pharmacological treatments, although the data for cannabinoids is encouraging in those with FXS and in future developments in gene therapy may provide the answer to the search for precision medicine. Treatment must be person-centered and consider the combination of medical, genetic, cognitive and emotional challenges.PMID:38393835 | DOI:10.1080/14656566.2024.2323605 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - February 23, 2024 Category: Drugs & Pharmacology Authors: Lance V Watkins Seungyoun Moon Lisa Burrows Samuel Tromans Julian Barwell Rohit Shankar Source Type: research
